Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01228396
Other study ID # DIMS04
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received September 26, 2010
Last updated August 16, 2011
Start date May 2009
Est. completion date March 2012

Study information

Verified date August 2011
Source Daval International Limited
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

Patients with marked bladder dysfunction as a result of secondary progressive multiple sclerosis are being recruited to receive AIMSPRO or placebo by subcutaneous injection, in this double-blind crossover study.


Description:

Treatment periods of 4 weeks' duration are separated by a 6 week wash-out phase. After 14 weeks of randomised therapy there is a 38 week period of "open-label" AIMSPRO treatment.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date March 2012
Est. primary completion date May 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- M / F aged 18 years or older.

- Patients of childbearing potential must use adequate birth control measures for the duration of the study and 6 months after receiving the last injection of AIMSPRO.

- Clinically definite SPMS.

- Ambulant, walking aids allowed.

- No more than one relapse within the last 12 months and no relapse within the last 6 months.

- Urinary frequency of at least 8 times per 24-hours.

- Urinary urgency with or without urge incontinence.

- MRI brain or spinal cord abnormalities consistent with MS.

- Screening laboratory test results must meet the following criteria:

- Haemoglobin > 9.5 g/dL

- WBC > 3.5 x 109/L

- Neutrophils > 1.5 x 109/L

- Platelets > 100 x 109/L

- Baseline AST , alkaline phosphatase, Thyroid function, Serum Electrophoresis levels must be within the normal range.

- Able to adhere to the study visit schedule and other protocol requirements

- Capable of giving written informed consent.

Exclusion Criteria:

- Acute symptomatic urinary infection.

- Taking DDAVP or antimuscarinic agents.

- Full time wheelchair user.

- Immunosuppressant drug therapy of any kind in the last 3 months.

- Relapse within the last 6 months.

- No clear progression of disability in the last 12 months.

- Co-existent medical condition precluding participation, including any history of severe allergic reaction.

- Pregnant or lactating women and women who are planning pregnancy within 12 months of screening (i.e., approximately 6 months following last injection).

- Receipt of any investigational drug within 30 days prior to screening or within 5 half-lives of the investigational agent, whichever is longer.

- Treatment with any therapeutic agent targeted at reducing TNF (e.g., infliximab, pentoxifylline, thalidomide, etanercept, etc.) within 3 months of screening.

- Previous administration of AIMSPRO.

- Ongoing corticosteroid therapy or any corticosteroids within the previous 3 months.

- History of known allergy to animal proteins, tuberculosis.

- Serious infections (such as pneumonia or pyelonephritis) in the previous 3 months. Less serious infections such as acute upper respiratory tract infection or simple urinary tract infection, should be followed to their conclusion or treated, as appropriate, prior to inclusion.

- Patients with opportunistic infections within the previous 6 months.

- Established malignant disease, renal, hepatic, haematologic, gastrointestinal, endocrine, pulmonary, or cardiac disease.

- Significant other neurological disorder.

- Presence of a transplanted organ, with the exception of a corneal transplant > 3 months prior to screening.

- Lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location (such as nodes in the posterior triangle of the neck, infra-clavicular, epitrochlear, or periaortic areas), or splenomegaly.

- Recent clinically significant substance abuse (drug or alcohol).

- Poor tolerability of venipuncture.

- Investigational drugs or drugs targeted at reducing TNF are not allowed during participation in the study.

- Patients will not be permitted to receive immunosuppressive treatment during this study. The exception will be where a patient's treating neurologist determines that a course of steroid therapy, oral or intravenous, is required in view of a sufficiently disabling relapse of MS.

- Immunosuppressive therapy within the month prior to entry into the study.

- Taking the licensed anticonvulsant medication lamotrigine or the anti-arrhythmic drug flecainide, both of which are potent sodium channel blocking agents.

- Unable to fill in the criteria related to bladder dysfunction status.

- Unable to give written informed consent.

- Use of intermittent or indwelling urinary catheter.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Hyperimmune caprine serum against HIV lysate
1.0ml solution for subcutaneous injection (4.5mg total protein / ml) twice weekly for 4 weeks

Locations

Country Name City State
United Kingdom Royal Free Hospital Hampstead NHS Trust London

Sponsors (1)

Lead Sponsor Collaborator
Daval International Limited

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in average voided volume The change is calculated as the value at the later time point minus the value at the earlier time point for weeks 0 to 4 and weeks 10 to 14 respectively. At 0, 4, 10 and 14 weeks No
Secondary Change in average 24-hour frequency The change is calculated as the value at the later time point minus the value at the earlier time point for weeks 0 to 4 and weeks 10 to 14 respectively. At 0, 4, 10 and 14 weeks No
Secondary Change in visual acuity and colour vision Employs logMAR based and Farnsworth-Munsell 100 Hue testing. The change is calculated as the value at the later time point minus the value at the earlier time point for weeks 0 to 4 and weeks 10 to 14 respectively. At 0, 4, 10 and 14 weeks No
Secondary Change in average 24-hour incontinence The change is calculated as the value at the later time point minus the value at the earlier time point for weeks 0 to 4 and weeks 10 to 14 respectively. At 0, 4, 10 and 14 weeks No
Secondary Change in urgency score The change is calculated as the value at the later time point minus the value at the earlier time point for weeks 0 to 4 and weeks 10 to 14 respectively. At 0, 4, 10 and 14 weeks No
Secondary Change in I-QOL score The Incontinence - Quality of Life questionnaire is administered at the beginning and end of each four week treatment phase. The change is calculated as the value at the later time point minus the value at the earlier time point for weeks 0 to 4 and weeks 10 to 14 respectively. At 0, 4, 10 and 14 weeks No
Secondary Change in Whittington Urgency Score The Whittington Urgency Score is administered at the beginning and end of each four week treatment phase. The change is calculated as the value at the later time point minus the value at the earlier time point for weeks 0 to 4 and weeks 10 to 14 respectively. At 0, 4, 10 and 14 weeks No
Secondary Change in Kurtzke EDS The Kurtzke EDS assessment is undertaken at the beginning and end of each four week treatment phase. The change is calculated as the value at the later time point minus the value at the earlier time point for weeks 0 to 4 and weeks 10 to 14 respectively. At 0, 4, 10 and 14 weeks No
Secondary Change in MSIS-29 The Multiple Sclerosis Impact Scale is administered at the beginning and end of each four week treatment phase. The change is calculated as the value at the later time point minus the value at the earlier time point for weeks 0 to 4 and weeks 10 to 14 respectively. At 0, 4, 10 and 14 weeks No
Secondary Change in MS FC The The Multiple Sclerosis Functional Composite assessment is undertaken at the beginning and end of each four week treatment phase. The change is calculated as the value at the later time point minus the value at the earlier time point for weeks 0 to 4 and weeks 10 to 14 respectively. At 0, 4, 10 and 14 weeks No
Secondary Change in MS WS The Multiple Sclerosis Walking Scale is assessed at the beginning and end of each four week treatment phase. The change is calculated as the value at the later time point minus the value at the earlier time point for weeks 0 to 4 and weeks 10 to 14 respectively. At 0, 4, 10 and 14 weeks No
See also
  Status Clinical Trial Phase
Completed NCT04239664 - Acceptance Based Telephone Support When Transitioning to SPMS N/A
Active, not recruiting NCT04411641 - Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) Phase 3
Completed NCT02549703 - Mitochondrial Dysfunction and Disease Progression
Terminated NCT01416181 - A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis Phase 3
Withdrawn NCT01181089 - Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS) Phase 1/Phase 2
Active, not recruiting NCT03471338 - Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme N/A
Withdrawn NCT05029609 - Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS Phase 1
Completed NCT02228213 - Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis Phase 2
Terminated NCT02296346 - Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis N/A
Completed NCT00559702 - Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) Phase 1
Terminated NCT03283826 - Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis Phase 1/Phase 2
Completed NCT02253264 - A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients Phase 1
Completed NCT01737372 - A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis N/A
Completed NCT00257855 - A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis Phase 2
Recruiting NCT06292923 - A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients Phase 2
Completed NCT03896217 - Simvastatin in Secondary Progressive Multiple Sclerosis Phase 2
Completed NCT02495766 - Autologous Mesenchymal Stromal Cells for Multiple Sclerosis Phase 1/Phase 2
Completed NCT00813969 - Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS Phase 1
Completed NCT01077466 - Natalizumab Treatment of Progressive Multiple Sclerosis Phase 2
Terminated NCT00146159 - Study Evaluating Mitoxantrone in Multiple Sclerosis Phase 3